Uterine Fibroids Market

Market Overview:

The 7 major uterine fibroids markets are expected to exhibit a CAGR of 2.99% during 2024-2034.

The uterine fibroids market has been comprehensively analyzed in IMARC's new report titled "Uterine Fibroids Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Uterine fibroids, also known as leiomyomas, refer to noncancerous growths that develop in the muscular wall of the uterus (womb). Most women suffering from this ailment do not experience any symptoms. However, depending on their size, location, and number, fibroids can cause a range of indications, such as heavy or prolonged menstrual periods, pelvic pain or pressure, frequent urination, difficulty emptying the bladder completely, constipation, backache or leg pain, enlargement of the abdomen, pain during sexual intercourse, etc. In severe cases, patients may also experience infertility or recurrent miscarriages. The diagnosis of uterine fibroids is usually made through a combination of the patient's medical history, characteristic findings, and pelvic examination. Several other diagnostic procedures, including magnetic resonance imaging and transabdominal or transvaginal ultrasound, are also utilized for assessing the size and location of fibroids and determining their impact on surrounding structures. The healthcare provider may further perform hysterosalpingography, which involves injecting a contrast dye into the uterus and fallopian tubes to detect submucosal fibroids and evaluate the patency of the fallopian tubes.

The rising cases of hormonal imbalances, which can disrupt the normal balance between estrogen and progesterone, are primarily driving the uterine fibroids market. In addition to this, the increasing incidences of several risk factors, including early onset of menstruation, nulliparity, high intake of red meat, genetic predisposition, obesity, etc., are also bolstering the market growth. Furthermore, the widespread adoption of levonorgestrel-releasing intrauterine devices (IUDs), since they can help to control heavy bleeding associated with the disease and provide symptomatic relief in women, is acting as another significant growth-inducing factor. Apart from this, the escalating demand for gonadotropin-releasing hormone (GnRH) agonists, which work by suppressing the production of estrogen and progesterone, thereby reducing the size of fibroids and inducing a temporary state of menopause, is also creating a positive outlook for the market. Moreover, the inflating utilization of magnetic resonance-guided focused ultrasound surgery, a noninvasive procedure that uses ultrasound waves to heat and destroy abnormal tissue without incisions, is expected to drive the uterine fibroids market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the uterine fibroids market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for uterine fibroids and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the uterine fibroids market in any manner.

Key Highlights:

• Uterine fibroids are the most prevalent benign tumor in women, affecting 40% to 80% of those with a uterus.
• Uterine fibroids affect one in every four adult women.
• Uterine fibroids are most frequent in adults between 30 and 50 years old and less common in people who have not had their first period or have entered menopause.
• Most women with uterine fibroids are asymptomatic; however, approximately 30% will develop significant symptoms.
• According to a study, women with new-onset hypertension had a 45% higher risk of acquiring fibroids than women who had never had hypertension before.
• Uterine fibroids are detected in up to 70% of white women and more than 80% of women of African descent during their lifespan.

Drugs:

LUPRON DEPOT (leuprolide acetate for depot suspension) 3.75 mg or 11.25 mg in combination with iron therapy is used before fibroid surgery to alleviate anemia caused by vaginal bleeding from uterine fibroids in individuals who require 3 months of hormone suppression. LUPRON DEPOT treatment has a maximum duration of three months.

Myfembree (Estradiol/norethisterone acetate/relugolix) is a combination of relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg. The combination drug is a once-daily oral tablet approved to treat heavy menstrual bleeding due to uterine fibroids and moderate to severe pain from endometriosis.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the uterine fibroids market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the uterine fibroids market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current uterine fibroids marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the uterine fibroids market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the uterine fibroids market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the uterine fibroids market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of uterine fibroids across the seven major markets?
• What is the number of prevalent cases (2018-2034) of uterine fibroids by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of uterine fibroids by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with uterine fibroids across the seven major markets?
• What is the size of the uterine fibroids patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of uterine fibroids?
• What will be the growth rate of patients across the seven major markets?
   

Uterine Fibroids: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for uterine fibroids drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the uterine fibroids market?
• What are the key regulatory events related to the uterine fibroids market?
• What is the structure of clinical trial landscape by status related to the uterine fibroids market?
• What is the structure of clinical trial landscape by phase related to the uterine fibroids market?
• What is the structure of clinical trial landscape by route of administration related to the uterine fibroids market?